These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 26507078)

  • 1. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.
    Nicholson A; Mahon J; Boland A; Beale S; Dwan K; Fleeman N; Hockenhull J; Dundar Y
    Health Technol Assess; 2015 Oct; 19(87):i-xxxi, 1-191. PubMed ID: 26507078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
    Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
    Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation.
    Fraser H; Gallacher D; Achana F; Court R; Taylor-Phillips S; Nduka C; Stinton C; Willans R; Gill P; Mistry H
    Health Technol Assess; 2020 Jun; 24(31):1-232. PubMed ID: 32605705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?
    Porpiglia F; Russo F; Manfredi M; Mele F; Fiori C; Bollito E; Papotti M; Molineris I; Passera R; Regge D
    J Urol; 2014 Jul; 192(1):60-6. PubMed ID: 24518780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
    Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
    Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis.
    Llewellyn A; Phung TH; O Soares M; Shepherd L; Glynn D; Harden M; Walker R; Duarte A; Dias S
    Health Technol Assess; 2024 Oct; 28(61):1-310. PubMed ID: 39367754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
    Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
    J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer.
    Huxley N; Jones-Hughes T; Coelho H; Snowsill T; Cooper C; Meng Y; Hyde C; Mújica-Mota R
    Health Technol Assess; 2015 Jan; 19(2):v-xxv, 1-215. PubMed ID: 25586547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2014 Apr; 16(4):338-46. PubMed ID: 24071797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
    Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
    Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
    Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation.
    Thurgar E; Barton S; Karner C; Edwards SJ
    Health Technol Assess; 2016 Mar; 20(24):v-vi, 1-486. PubMed ID: 27034016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
    Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
    J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
    Bresnahan R; Duarte R; Mahon J; Beale S; Chaplin M; Bhattacharyya D; Houten R; Edwards K; Nevitt S; Maden M; Boland A
    Health Technol Assess; 2023 Jul; 27(10):1-115. PubMed ID: 37839810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect.
    Perlis N; Al-Kasab T; Ahmad A; Goldberg E; Fadak K; Sayyid R; Finelli A; Kulkarni G; Hamilton R; Zlotta A; Ghai S; Fleshner N
    J Urol; 2018 May; 199(5):1182-1187. PubMed ID: 29175542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.
    Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB
    Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.